Astec LifeSciences Limited (NSE:ASTEC)

Market Cap	15.79B -11.9%
Revenue (ttm)	4.41B +9.3%
Net Income	-665.97M
EPS	-30.16
Shares Out	22.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	71,096
Open	712.05
Previous Close	722.75
Day's Range	684.80 - 725.40
52-Week Range	513.40 - 941.75
Beta	0.17
Analysts	Hold
Price Target	670.00 (-5.74%)
Est. Earnings	Oct 30, 2026

About Astec LifeSciences

Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat; post-harvest drench; and food additive and wood preservatives. It also provides herbicides, inse...

• Industry: Agricultural Inputs
• Sector: Materials
• Founded: 1994
• Employees: 471
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ASTEC

Financial Performance

In fiscal year 2026, Astec LifeSciences's revenue was 4.48 billion, an increase of 17.53% compared to the previous year's 3.81 billion. Losses were -809.18 million, -39.95% less than in 2025.

Analyst Summary

According to 2 analysts, the average rating for ASTEC stock is "Hold." The 12-month stock price target is ₹670.00, which is a decrease of -5.74% from the latest price.

Price Target

₹670.00

(-5.74% downside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error